Cannabinoids as New Drug Candidates for the Treatment of Glaucoma.
Erin JordanGia-Nam NguyenAlexander PiechotOliver KayserPublished in: Planta medica (2022)
Glaucoma is a blinding eye disease that affects about 70 million patients globally today. The cannabinoid receptors and the endocannabinoid system have found attention for new drug concepts. This review will analyze the potential of cannabinoids, primarily tetrahydrocannabinol, THCVS, and cannabinol, as drug candidates and the role of CB1/CB2 receptors with regard to the pathophysiology of glaucoma. The mode of action of cannabinoids as innovative drug candidates and recent formulations for topical delivery will be discussed. Cannabinoid receptors with associated TRPV channels will be evaluated for their potential as drug targets. Especially the role of the endocannabinoid system (fatty acid amide hydrolase, monoacylglycerol lipase) impacting the prostaglandin network (cyclooxygenase, PGE, PGF) and neuroprotection by inhibition of nitric oxide radical formation is in the focus of this review. Delivery systems, including recent clinical trials, will be analyzed to evaluate the potential for innovative future ophthalmological drugs.
Keyphrases
- nitric oxide
- clinical trial
- end stage renal disease
- fatty acid
- drug induced
- adverse drug
- chronic kidney disease
- human health
- randomized controlled trial
- newly diagnosed
- emergency department
- working memory
- risk assessment
- peritoneal dialysis
- nitric oxide synthase
- spinal cord
- hydrogen peroxide
- climate change
- blood brain barrier
- wound healing
- patient reported